Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Clorox Co    CLX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

The Clorox Company : Refutes Silent Spring Institute's Study on Our Consumer Products

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2012 | 03:26pm CET

We have reviewed the findings of Silent Spring's study claiming some U.S. consumer products contain endocrine-disrupting and asthma-related ingredients.

Product safety is a top priority at The Clorox Company and our company guidelines prohibit using endocrine-disrupting ingredients in our products. For those household products containing fragrance ingredients some consider to be asthma related, these ingredients are present at such low concentrations they do not cause irritation or trigger asthma when used as directed.

Our highly skilled scientists evaluate each product's safety, efficacy and regulatory compliance before it makes it to store shelves. Our safety assessments begin with analysis of each of the materials that go into making the product. This includes consideration of short-term and long-term impact from all types of exposures, including incidental or accidental, and routes of exposure such as skin, eye, ingestion and inhalation. Our safety evaluation also includes the assessment of fragrances, dyes, and preservatives, and other proprietary ingredients, in our formulations.

Clorox voluntarily discloses all ingredients for our U.S. and Canadian household cleaning and disinfecting products through our industry-leading initiative, Ingredients Inside (www.IngredientsInside.com), which is available on our corporate web site and mobile platforms.

For more information on our product stewardship guidelines, visit http://www.thecloroxcompany..


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLOROX CO
12/07 CLOROX : New Study Reveals Women May Suffer From Digestive Health Issues In Sile..
12/07 CLOROX : Recognized as 'Best Place to Work' by Human Rights Campaign, Glassdoor
12/05 CLOROX : Take a 360 View into How Safe Water Can Change a Community
12/01 CLOROX : Patent Issued for Targeted Performance of Hypohalite Methods (USPTO 949..
11/18 CLOROX : Pine-Sol® Launches "Makers of Home"
11/17 CLOROX CO /DE/ : Change in Directors or Principal Officers, Submission of Matter..
11/17 CLOROX : Patent Issued for Refill Article for Wipes Dispenser and Assembly of Bo..
11/17 CLOROX : reg; and Sickweather Partner to Wipe Out FluFOMO
11/16 CLOROX : Declares Regular Quarterly Dividend of 80 Cents Per Share
11/03 CLOROX : Tampa Gets America's Heaviest Dose of Negative Presidential Campaign Ad..
More news
Sector news : Household Products - NEC
10/19DJEuropean Stocks Edge Lower After China Growth Holds Steady -- Update
10/19DJRECKITT BENCKISER : Reports Modest Growth in 3Q Comparable Sales
10/17DJRECKITT BENCKISER : 3Q 2016 - Forecast
09/23DJINDIVIOR : Shares Plunge as More US States Join Lawsuit -- Update
09/23 INDIVIOR : U.S. states sue opioid-maker Indivior, alleging anticompetitive pract..
More sector news : Household Products - NEC
News from SeekingAlpha
12/07 CLOROX : As Shares Near A 52-Week Low, An Insider Makes A $500,000 Purchase
12/06 The Most And Least Loved Stocks In The S&P 500
12/05 DIVIDEND INCOME UPDATE : November 2016
12/04 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Fldm, amh, spke, infi
11/30 A Guide To Investing In Water
Advertisement
Financials ($)
Sales 2017 5 969 M
EBIT 2017 1 118 M
Net income 2017 697 M
Debt 2017 1 886 M
Yield 2017 2,81%
P/E ratio 2017 21,76
P/E ratio 2018 20,30
EV / Sales 2017 2,80x
EV / Sales 2018 2,71x
Capitalization 14 843 M
More Financials
Chart CLOROX CO
Duration : Period :
Clorox Co Technical Analysis Chart | CLX | US1890541097 | 4-Traders
Full-screen chart
Technical analysis trends CLOROX CO
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 121 $
Spread / Average Target 5,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Benno O. Dorer Chairman & Chief Executive Officer
Stephen M. Robb Chief Financial Officer & Executive Vice President
James E. Foster EVP-Information Technology & Product Supply
Robert W. Matschullat Lead Independent Director
Carolyn M. Ticknor Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CLOROX CO-9.10%14 843
RECKITT BENCKISER GROU..5.08%58 096
UNILEVER INDONESIA TBK..--.--%23 720
CHURCH & DWIGHT CO., I..4.43%11 461
LION CORP59.64%4 658
KOBAYASHI PHARMACEUTIC..-2.63%3 544
More Results